Cargando…

The Q(i) Site of Cytochrome b is a Promiscuous Drug Target in Trypanosoma cruzi and Leishmania donovani

[Image: see text] Available treatments for Chagas’ disease and visceral leishmaniasis are inadequate, and there is a pressing need for new therapeutics. Drug discovery efforts for both diseases principally rely upon phenotypic screening. However, the optimization of phenotypically active compounds i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wall, Richard J., Carvalho, Sandra, Milne, Rachel, Bueren-Calabuig, Juan A., Moniz, Sonia, Cantizani-Perez, Juan, MacLean, Lorna, Kessler, Albane, Cotillo, Ignacio, Sastry, Lalitha, Manthri, Sujatha, Patterson, Stephen, Zuccotto, Fabio, Thompson, Stephen, Martin, Julio, Marco, Maria, Miles, Timothy J., De Rycker, Manu, Thomas, Michael G., Fairlamb, Alan H., Gilbert, Ian H., Wyllie, Susan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2020
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076694/ https://www.ncbi.nlm.nih.gov/pubmed/31967783 http://dx.doi.org/10.1021/acsinfecdis.9b00426

Ejemplares similares

Pharmacological Validation of N-Myristoyltransferase as a Drug Target in Leishmania donovani
por: Corpas-Lopez, Victoriano, et al.
Publicado: (2018)

Chemical Validation of Methionyl-tRNA Synthetase as a Druggable Target in Leishmania donovani
por: Torrie, Leah S., et al.
Publicado: (2017)

Development of Trypanosoma cruzi in vitro assays to identify compounds suitable for progression in Chagas’ disease drug discovery
por: MacLean, Lorna M., et al.
Publicado: (2018)

Development and Validation of a Novel Leishmania donovani Screening Cascade for High-Throughput Screening Using a Novel Axenic Assay with High Predictivity of Leishmanicidal Intracellular Activity
por: Nühs, Andrea, et al.
Publicado: (2015)

Automated High-Content Assay for Compounds Selectively Toxic to Trypanosoma cruzi in a Myoblastic Cell Line
por: Alonso-Padilla, Julio, et al.
Publicado: (2015)

Novel chemical starting points for drug discovery in leishmaniasis and Chagas disease
por: Roquero, Irene, et al.
Publicado: (2019)

Identification of Novel Trypanosoma cruzi Proteasome Inhibitors Using a Luminescence-Based High-Throughput Screening Assay
por: Zmuda, Filip, et al.
Publicado: (2019)

Rate-of-Kill (RoK) assays to triage large compound sets for Chagas disease drug discovery: Application to GSK Chagas Box
por: Cantizani, Juan, et al.
Publicado: (2021)

Cyclin-dependent kinase 12, a novel drug target for visceral leishmaniasis
por: Wyllie, Susan, et al.
Publicado: (2018)

Unravelling the rate of action of hits in the Leishmania donovani box using standard drugs amphotericin B and miltefosine
por: Tegazzini, Diana, et al.
Publicado: (2017)

Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition
por: Wyllie, Susan, et al.
Publicado: (2019)

Instability of aquaglyceroporin (AQP) 2 contributes to drug resistance in Trypanosoma brucei
por: Quintana, Juan F., et al.
Publicado: (2020)

Biochemical and genetic characterization of Trypanosoma cruzi N-myristoyltransferase
por: Roberts, Adam J., et al.
Publicado: (2014)

Identification of Trypanocidal Activity for Known Clinical Compounds Using a New Trypanosoma cruzi Hit-Discovery Screening Cascade
por: De Rycker, Manu, et al.
Publicado: (2016)

Trypanosoma cruzi Phosphomannomutase and Guanosine Diphosphate-Mannose Pyrophosphorylase Ligandability Assessment
por: Zmuda, Filip, et al.
Publicado: (2019)

Carbonic anhydrases from Trypanosoma cruzi and Leishmania donovani chagasi are inhibited by benzoxaboroles
por: Nocentini, Alessio, et al.
Publicado: (2017)

Structure-Guided Design and Synthesis of a Pyridazinone Series of Trypanosoma cruzi Proteasome Inhibitors
por: Thomas, Michael G., et al.
Publicado: (2023)

Characterisation of a putative glutamate 5‐kinase from Leishmania donovani
por: Sienkiewicz, Natasha, et al.
Publicado: (2018)

The N-myristoylome of Trypanosoma cruzi
por: Roberts, Adam J., et al.
Publicado: (2016)

Identification of inhibitors of an unconventional Trypanosoma brucei kinetochore kinase
por: Torrie, Leah S., et al.
Publicado: (2019)

The R Enantiomer of the Antitubercular Drug PA-824 as a Potential Oral Treatment for Visceral Leishmaniasis
por: Patterson, Stephen, et al.
Publicado: (2013)

Elucidation of Ligand-Dependent Modulation of Disorder-Order Transitions in the Oncoprotein MDM2
por: Bueren-Calabuig, Juan A., et al.
Publicado: (2015)

Live-imaging rate-of-kill compound profiling for Chagas disease drug discovery with a new automated high-content assay
por: Svensen, Nina, et al.
Publicado: (2021)

Identification of a Proteasome-Targeting Arylsulfonamide with Potential for the Treatment of Chagas’ Disease
por: Lima, Marta L., et al.
Publicado: (2022)

A Static-Cidal Assay for Trypanosoma brucei to Aid Hit Prioritisation for Progression into Drug Discovery Programmes
por: De Rycker, Manu, et al.
Publicado: (2012)

Scaffold-Hopping Strategy on a Series of Proteasome Inhibitors Led to a Preclinical Candidate for the Treatment of Visceral Leishmaniasis
por: Thomas, Michael, et al.
Publicado: (2021)

Appraisal of anti-protozoan activity of nitroaromatic benzenesulfonamides inhibiting carbonic anhydrases from Trypanosoma cruzi and Leishmania donovani
por: Nocentini, Alessio, et al.
Publicado: (2019)

Unraveling the Differences of the Hydrolytic Activity of Trypanosoma cruzitrans-Sialidase and Trypanosoma rangeli Sialidase: A Quantum Mechanics–Molecular Mechanics Modeling Study
por: Bueren-Calabuig, Juan A., et al.
Publicado: (2014)

Comment on “The translational challenge in Chagas disease drug development” by Kratz et al.
por: De Rycker, Manu
Publicado: (2022)

Anti-trypanosomatid drug discovery: progress and challenges
por: De Rycker, Manu, et al.
Publicado: (2022)

Identification and Optimization of a Series of 8-Hydroxy Naphthyridines with Potent In Vitro Antileishmanial Activity: Initial SAR and Assessment of In Vivo Activity
por: Thomas, Michael G., et al.
Publicado: (2020)

Promiscuous words
por: Elgar, Mark A, et al.
Publicado: (2013)

Promiscuous Ligands
por: McGovern, S.L.
Publicado: (2007)

Are PARPs promiscuous?
por: Feijs, Karla L.H., et al.
Publicado: (2022)

Data structures for compound promiscuity analysis: promiscuity cliffs, pathways and promiscuity hubs formed by inhibitors of the human kinome
por: Miljković, Filip, et al.
Publicado: (2019)

A comparative study of methylglyoxal metabolism in trypanosomatids
por: Greig, Neil, et al.
Publicado: (2009)

Antimonial Resistance in Leishmania donovani Is Associated with Increased In Vivo Parasite Burden
por: Vanaerschot, Manu, et al.
Publicado: (2011)

Mechanism of allosteric activation of human mRNA cap methyltransferase (RNMT) by RAM: insights from accelerated molecular dynamics simulations
por: Bueren-Calabuig, Juan A, et al.
Publicado: (2019)

Linking In Vitro and In Vivo Survival of Clinical Leishmania donovani Strains
por: Vanaerschot, Manu, et al.
Publicado: (2010)

Promiscuous drugs compared to selective drugs (promiscuity can be a virtue)
por: Mencher, Simon K, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_v1cvgg458e0de10a09hge7qviu